JP Morgan Maintains Overweight on IQVIA Hldgs, Raises Price Target to $288
IQVIA Hldgs Analyst Ratings
Argus Research Maintains IQVIA Holdings(IQV.US) With Buy Rating
Stifel Maintains IQVIA Holdings(IQV.US) With Buy Rating, Raises Target Price to $312
Stifel Nicolaus Remains a Buy on IQVIA Holdings (IQV)
Jefferies Downgrades IQVIA to Hold, Cites Subdued Market Outlook
Jefferies Downgrades IQVIA Holdings(IQV.US) to Hold Rating, Cuts Target Price to $242
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $242 to $275
Jefferies Downgrades IQVIA Holdings to Hold From Buy, Adjusts Price Target to $242 From $266
IQVIA Holdings: A Strong Buy on Robust R&D and Tech Growth Prospects
IQVIA Holdings Outperforms With Strong Q2 Results and Positive Growth Outlook: Cherny Maintains Buy Rating
HSBC Adjusts Price Target on IQVIA to $290 From $280
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $251 to $300
IQVIA Holdings Price Target Raised to $251.00/Share From $235.00 by Baird
IQVIA Hldgs Analyst Ratings
Evercore ISI Adjusts Price Target on IQVIA Holdings to $270 From $230, Maintains Outperform Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Vertex Pharmaceuticals (VRTX) and Gilead Sciences (GILD)
IQVIA Holdings: Strong Q2 Performance and Raised Annual Guidance Prompt 'Buy' Rating
Barclays Sticks to Its Buy Rating for IQVIA Holdings (IQV)
IQVIA Holdings: Strong H2 Outlook With Buoyant TAS, RWE, and RDS Segments Driving Buy Rating